Orally active purine-based inhibitors of heat shock protein 90

Details Orally active purine-based inhibitors of heat shock protein 90 Orally active purine-based inhibitors of heat shock protein 90

C - Chemistry, Metallurgy

07

D

C07D 473/34 (2006.01) A61K 31/52 (2006.01)

Patent

CA 2634723

Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same. Methods of using the novel purine compounds of the invention,and tautomers and pharmaceutically acceptable salts thereof, include their use in inhibiting heat shock protein 90's (HSP90*s) to thereby treat or prevent HSP90-dependent diseases, e.g., proliferative disorders such as breast cancer.

La présente invention concerne des composés de purine innovants, leurs tautomères et leurs sels pharmaceutiquement acceptables ainsi que les compositions pharmaceutiquement et les complexes qui les comprennent, par exemple les complexes de HSP90, et leurs procédés d'utilisation. Les procédés d'utilisation des composés de purine innovants de l'invention, de leurs tautomères et de leurs sels pharmaceutiquement acceptables incluent leur utilisation pour inhiber les protéines de choc thermique 90 (HSP90) afin de traiter ou de prévenir les maladies liées aux HSP90, par exemple les troubles prolifératifs tels que le cancer du sein.

Affiliated with

Also associated with

Rating

Orally active purine-based inhibitors of heat shock protein 90 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Orally active purine-based inhibitors of heat shock protein 90, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally active purine-based inhibitors of heat shock protein 90 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2059732